Application of microarrays for the prediction of therapy response in breast cancer

Cancer Genomics and Proteomics

Volumn 2, Issue 5, 2005, Pages 255-263

  Györffy, Balazs ^a,b   Surowiak, Pawel ^a,c   Lage, Hermann ^a,d  

^a HUMBOLDT UNIVERSITY   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Breast cancer; cDNA microarrays; Differential gene expression; Drug resistance; Response prediction; Review

Indexed keywords

ABC TRANSPORTER; ANTHRACYCLINE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CISPLATIN; COUMAMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ETOPOSIDE; FLAVOPIRIDOL; FLUOROURACIL; FULVESTRANT; METALLOTHIONEIN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NOVOBIOCIN; PACLITAXEL; RALOXIFENE; TAMOXIFEN; TOPOTECAN; TOREMIFENE; TRASTUZUMAB; TUMOR MARKER; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER SURVIVAL; CONCENTRATION RESPONSE; DNA MICROARRAY; DRUG RESPONSE; GENE EXPRESSION; GENE IDENTIFICATION; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MULTIDRUG RESISTANCE; PREDICTION; PROGNOSIS; REVIEW;

VINCA;

EID: 27144469539     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Ferlay J, Bray F, Sankila R and Parkin DM: EUCAN: Cancer Incidence, Mortality and Prevalence in the European Union 1998, version 5.0, IARC Cancerbase No.5. Lyon, IARC Press, 1999
2. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y and Hilakivi-Clarke LA: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339, 2003.
3. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942, 1998.
4. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15, 1992.
5. Clarke R, Brunner N, Katzenellenbogen BS, Thompson EW, Norman MJ, Koppi C, Paik S, Lippman ME and Dickson RB: Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci USA 86: 3649-3653, 1989.
6. Cole MP, Jones CT and Todd ID: A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25: 270-275, 1971.
7. Hayashi SI, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, Yoshida N and Yamaguchi Y: The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer 10: 193-202, 2003.
8. Conneely OM and Lydon JP: Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 65: 571-577, 2000.
9. Hilakivi-Clarke L, Cabanes A, Olivo S, Kerr L, Bouker KB and Clarke R: Do estrogens always increase breast cancer risk? J Steroid Biochem Mol Biol 80: 163-174, 2002.
10. Lage H: ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 22: 188-199, 2003.
11. Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I and Gottesman MM: Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 232: 643-645, 1986.
12. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
13. Doyle LA and Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358, 2003.
14. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
15. Lage H: Drug resistance in breast cancer. Cancer Ther 1: 81-92, 2003.
16. Leonard GD, Fojo T and Bates SE: The role of ABC transporters in clinical practice. Oncologist 8: 411-424, 2003.
17. Allen JD and Schinkel AH: Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 1: 427-434, 2002.
18. Woehlecke H, Osada H, Herrmann A and Lage H: Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. Int J Cancer 107: 721-728, 2003.
19. Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD and Kohno S: Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer 108: 146-151, 2004.
20. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 339: 974-984, 1998.
21. Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481, 1999.
22. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.
23. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME and Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289, 1992.
24. Albanell J and Baselga J: Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst 93: 1830-1832, 2001.
25. Winston JS, Ramanaryanan J and Levine E: HER-2/neu evaluation in breast cancer: are we there yet? Am J Clin Pathol 121 Suppl: S33-49, 2004.
26. Duffy MJ: Predictive markers in breast and other cancers: a review. Clin Chem 51: 494-503, 2005.
27. Velculescu VE and El-Deiry WS: Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 42: 858-868, 1996.
28. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408(6810): 307-310, 2000,
29. Soussi T and Beroud C: Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1: 233-240, 2001.
30. Debatin KM and Krammer PH: Death receptors in chemotherapy and cancer. Oncogene 23: 2950-2966, 2004.
31. Trock BJ, Leonessa F and Clarke R: Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89: 917-931, 1997.
32. Wang CS, LaRue H, Fortin A, Gariepy G and Tetu B: mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy. Breast Cancer Res Treat 45: 63-74, 1997.
33. Abbaszadegan MR, Cress AE, Futscher BW, Bellamy WT and Dalton WS: Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res 56: 5435-5442, 1996.
34. Faneyte IF, Kristel PM and van de Vijver MJ: Determining MDR1/P-glycoprotein expression in breast cancer. Int J Cancer 93: 114-122, 2001.
35. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dorken B and Royer HD: Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3: 447-450, 1997.
36. Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornaffel J, Wojnar A, Pudelko M, Dietel M, Denkert C, Zabel M and Lage H: Relationship between cyclooxygenase 2 and MDR1/P-glycoprotein expressions in invasive breast cancers and their prognostic significance. Breast Cancer Res, in press, 2005.
37. Surowiak P, Matkowski R, Materna V, Györffy B, Wojnar A, Pudelko M, Dziegiel P, Kornafel J and Zabel M: Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance. Histol Histopathol 20: 9037-9044, 2005.
38. Steeg PS and Zhou Q: Cyclins and breast cancer. Breast Cancer Res Treat 52: 17-28, 1998.
39. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H and Schmitt M; German N0 Study Group: Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93: 913-920, 2001.
40. Bieche I and Lidereau R: Genetic alterations in breast cancer. Genes Chromosomes Cancer 14: 227-251, 1995.
41. Evans WE and Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature 429: 464-468, 2004.
42. Bertucci F, Van Hulst S, Bernard K, Loriod B, Granjeaud S, Tagett R, Starkey M, Nguyen C, Jordan B and Birnbaum D: Expression scanning of an array of growth control genes in human tumor cell lines. Oncogene 18: 3905-3912, 1999.
43. Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK, Osborne CK and Fuqua SA: Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst 91: 453-459, 1999.
44. Yang GP, Ross DT, Kuang WW, Brown PO and Weigel RJ: Combining SSH and cDNA microarrays for rapid identification of differentially expressed genes. Nucleic Acids Res 27: 1517-1523, 1999.
45. Hoch RV, Thompson DA, Baker RJ and Weigel RJ: GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 84: 122-128, 1999.
46. Bertucci F, Houlgatte R, Benziane A, Granjeaud S, Adelaide J, Tagett R, Loriod B, Jacquemier J, Viens P, Jordan B, Birnbaum D and Nguyen C: Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 9: 2981-2991, 2000.
47. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and Botstein D: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
48. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M and Iggo R: Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24: 4660-4671, 2005.
49. Jaiyesimi IA, Buzdar AU and Hortobagyi G: Inflammatory breast cancer: a review. J Clin Oncol 10: 1014-1024, 1992.
50. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Nguyen C, Maraninchi D, Jacquemier J, Houlgatte R, Birnbaum D and Viens P: Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 64: 8558-8565, 2004.
51. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
52. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO and Weinstein JN: A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244, 2000.
53. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES and Golub TR: Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98: 10787-10792, 2001.
54. Gillet JP, Efferth T, Steinbach D, Hamels J, de Longueville F, Bertholet V and Remacle J: Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 64: 8987-8993, 2004.
55. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC and O'Connell P: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369, 2003.
56. Hortobagyi G: Docetaxel in breast cancer and a rationale for combination therapy. Oncology (Williston Park) 11: 11-15, 1997.
57. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A and Crown J: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2354, 1999.
58. Aapro MS: Adjuvant therapy of primary breast cancer: a review of key findings from the 7th International Conference, St. Gallen, February 2001. Oncologist 6: 376-385, 2001.
59. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H and O'Connell P: Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23: 1169-1177, 2005.
60. Györffy B, Serra V, Jürchott K, Abdul-Ghani R, Garber M, Petersen I, Lage H, Dietel M and Schäfer R: Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug resistant cell lines correlates with patient survival. Oncogene, in press, 2005.
61. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL and Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.
62. Chen G, Jaffrezou JP, Fleming WH, Duran GE and Sikic BI: Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res 54: 4980-4987, 1994.
63. Turton NJ, Judah DJ, Riley J, Davies R, Lipson D, Styles JA, Smith AG and Gant TW: Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 20: 1300-1306, 2001.
64. Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS and Chin KV: Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 60: 4161-4166, 2000.
65. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN and Pusztai L: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22: 2284-2293, 2004.
66. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, Yoo BC, Kim HK and Park JG: Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 10: 272-284, 2004.
67. Troester MA, Hoadley KA, Sorlie T, Herbert BS, Borresen-Dale AL, Lonning PE, Shay JW, Kaufmann WK and Perou CM: Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 64: 4218-4226, 2004.
68. Györffy B, Surowiak P, Kiesslich O, Denkert C, Schäfer R, Dietel M and Lage H: Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer, in press, 2005.
69. Modlich O, Prisack HB, Munnes M, Audretsch W and Bojar H: Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 10: 6418-6431, 2004.
70. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK and Liu ET: Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4: R3, 2002.
71. Jarvinen AK, Hautaniemi S, Edgren H, Auvinen P, Saarela J, Kallioniemi OP and Monni O: Are data from different gene expression microarray platforms comparable? Genomics 83: 1164-1168, 2004.
72. Rogojina AT, Orr WE, Song BK and Geisert EE Jr: Comparing the use of Affymetrix to spotted oligonucleotide microarrays using two retinal pigment epithelium cell lines. Mol Vis 9: 482-496, 2003.
73. Lage H: Molecular analysis of therapy resistance in gastric cancer. Digest Dis 21: 326-338, 2003.
74. Ludwig A, Dietel M and Lage H: Identification of differentially expressed genes in classical and atypical multidrug-resistant gastric carcinoma cells. Anticancer Res 22: 3213-3222, 2002.
75. Heim S and Lage H: Transcriptome analysis of different multidrug-resistant gastric carcinoma cells. In Vivo 19: 583-590, 2005.
76. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SPC and Doyle LA: Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91: 429-433, 1999.
77. Lage H, Perlitz C, Abele R, Tampé R, Dietel M, Schadendorf D and Sinha P: Enhanced expression of human ABC-transporter TAP is associated with cellular resistance to mitoxantrone. FEBS Lett 503: 179-184, 2001.
78. Wichert A, Stege A, Midorikawa Y, Holm PS and Lage H: Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene 23: 945-955, 2004.
79. Storey JD and Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100: 9440-6445, 2003.
80. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J and Vingron M: Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29: 365-371, 2001.